High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
189.85M
+13.55%
0.700
-4.09%
189.65M
+12.86%
0.641
-7.16%
193.75M
+7.37%
0.631
+23.79%
Estimates Revision
The market is revising Upward the revenue expectations for U.S. Physical Therapy, Inc. (USPH) for FY2025, with the revenue forecasts being adjusted by 0.73% over the past three months. During the same period, the stock price has changed by 11.60%.
Revenue Estimates for FY2025
Revise Upward
+0.73%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.64%
In Past 3 Month
Stock Price
Go Up
+11.60%
In Past 3 Month
5 Analyst Rating
0Wall Street analysts forecast USPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for USPH is 107.00 USD with a low forecast of 98.00 USD and a high forecast of 113.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
0Current: 74.000
Low
98.00
Averages
107.00
High
113.00
0Current: 74.000
Low
98.00
Averages
107.00
High
113.00
JMP Securities
Constantine Davides
Buy
Reiterates
$113
2025-04-22
Reason
JMP Securities
Constantine Davides
Price Target
$113
2025-04-22
Reiterates
Buy
Reason
JP Morgan
Calvin Sternick
Buy
Maintains
$120 → $110
2025-03-19
Reason
JP Morgan
Calvin Sternick
Price Target
$120 → $110
2025-03-19
Maintains
Buy
Reason
JPMorgan lowered the firm's price target on U.S. Physical Therapy to $110 from $120 and keeps an Overweight rating on the shares. Following Q4 earnings, the firm is updating its estimates, noting that for 2025 it increased its revenue estimate to $747M while bringing down its adjusted EBITDA estimate to $91M. For 2026, the firm increased its revenue estimate to $794M while maintaining its adjusted EBITDA estimate at $101M, the analyst added.
Barrington Research
Michael Petusky
Buy
Maintains
$108 → $98
2025-02-28
Reason
Barrington Research
Michael Petusky
Price Target
$108 → $98
2025-02-28
Maintains
Buy
Reason
JMP Securities
Constantine Davides
Buy
Initiates
$113
2024-12-16
Reason
JMP Securities
Constantine Davides
Price Target
$113
2024-12-16
Initiates
Buy
Reason
B of A Securities
Joanna Gajuk
Hold
to
Strong Buy
Upgrades
$100 → $115
2024-12-16
Reason
B of A Securities
Joanna Gajuk
Price Target
$100 → $115
2024-12-16
Upgrades
Hold
to
Strong Buy
Reason
JP Morgan
Calvin Sternick
Buy
Maintains
$117 → $120
2024-12-03
Reason
JP Morgan
Calvin Sternick
Price Target
$117 → $120
2024-12-03
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for US Physical Therapy Inc (USPH.N) is 29.60, compared to its 5-year average forward P/E of 35.28. For a more detailed relative valuation and DCF analysis to assess US Physical Therapy Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
35.28
Current PE
29.60
Overvalued PE
39.88
Undervalued PE
30.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
21.07
Current EV/EBITDA
17.64
Overvalued EV/EBITDA
23.51
Undervalued EV/EBITDA
18.64
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
2.32
Current PS
1.45
Overvalued PS
2.80
Undervalued PS
1.85
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
USPH News & Events
Events Timeline
(ET)
2025-05-28
16:14:08
U.S. Physical Therapy announces dual listing on NYSE Texas
2025-05-07 (ET)
2025-05-07
16:27:21
U.S. Physical Therapy reports Q1 operating EPS 48c, consensus 45c
2025-03-03 (ET)
2025-03-03
07:31:19
U.S. Physical Therapy acquires three-clinic physical therapy practice in Wyoming
Sign Up For More Events
Sign Up For More Events
News
Preview
3.0
07-14NASDAQ.COMAdd Up The Parts: SLYG Could Be Worth $104
Preview
1.0
06-12NewsfilterU.S. Physical Therapy Presented at Investor Conferences
Preview
8.5
05-29NewsfilterU.S. Physical Therapy Announces Dual Listing on NYSE Texas
Sign Up For More News
People Also Watch
FAQ
What is US Physical Therapy Inc (USPH) stock price today?
What is US Physical Therapy Inc (USPH)'s business?
What is the price predicton of USPH Stock?
What is US Physical Therapy Inc (USPH)'s revenue for the last quarter?
What is US Physical Therapy Inc (USPH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for US Physical Therapy Inc (USPH)'s fundamentals?
How many employees does US Physical Therapy Inc (USPH). have?